Publication Name	World Journal of Diabetes
Manuscript ID	24977
Country	United States

Received	2016-02-16 17:07
Peer-Review Started	2016-02-17 16:44
To Make the First Decision	2016-04-15 08:49
Return for Revision	2016-04-20 17:36
Revised	2016-05-08 02:23
Second Decision	2016-06-29 10:54
Accepted by Journal Editor-in-Chief	2016-06-29 16:57
Accepted by Executive Editor-in-Chief	2016-07-13 11:52
Articles in Press	2016-07-13 11:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-08-16 17:13
Publish the Manuscript Online	2016-08-23 08:55

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Allergy
Manuscript Type	Minireviews
Article Title	Treatment of diabetic retinopathy: Recent advances and unresolved challenges
Manuscript Source	Invited Manuscript
All Author List	Michael W Stewart
Funding Agency and Grant Number
Corresponding Author	Michael W Stewart, MD, Department of Ophthalmology, Mayo Clinic Florida, 4500 San Pablo Rd., Jacksonville, FL 32224, United States. stewart.michael@mayo.edu
Key Words	Aflibercept; Bevacizumab; Dexamethasone delivery system; Diabetic macular edema; Ranibizumab; Macular photocoagulation; Panretinal photocoagulation; Proliferative diabetic retinopathy; Diabetic retinopathy; Fluocinolone acetonide insert
Core Tip	Newly introduced pharmacotherapies have contributed significantly to the treatment of diabetic retinopathy over the past 10 years and have become first-line therapy. Several questions regarding the best management of certain diabetic conditions remain and new therapies are needed to improve outcomes. Ongoing research and development should address many of these issues over the next 10 years.
Publish Date	2016-08-23 08:55
Citation	Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes 2016; 7(16): 333-341
URL	http://www.wjgnet.com/1948-9358/full/v7/i16/333.htm
DOI	http://dx.doi.org/10.4239/wjd.v7.i16.333

Full Article (PDF)	WJD-7-333.pdf
Full Article (Word)	WJD-7-333.doc
Manuscript File	24977-Review.docx
Answering Reviewers	24977-Answering reviewers.pdf
Audio Core Tip	24977-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	24977-Conflict-of-interest statement.pdf
Copyright License Agreement	24977-Copyright assignment.pdf
Peer-review Report	24977-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	24977-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	24977-Scientific misconduct check.pdf
Scientific Editor Work List	24977-Scientific editor work list.pdf